Corner Office Conversation with Dilip Shanghvi, Chairman of Sun Pharma and Glenn Saldanha, Managing Director at Glenmark Pharma

🎯 Core Theme & Purpose

This episode delves into the evolution and future of the Indian pharmaceutical industry, focusing on the critical role of innovation and strategic risk-taking. It offers insights into the challenges and opportunities faced by companies in a rapidly changing global landscape. The discussion is particularly valuable for entrepreneurs, investors, and leaders within the pharmaceutical and biotech sectors seeking to understand the dynamics of building and scaling innovative drug companies in India.

📋 Detailed Content Breakdown

• The Genesis of Sun Pharma and Glenmark: The episode highlights the contrasting yet complementary approaches of Dilip Shanghvi (Sun Pharma) and Glenn Saldanha (Glenmark). Shanghvi’s strategy involved ruthless capital discipline and occupying neglected market niches, while Saldanha bet on innovation over a 25-year period, even when it was unfashionable and angered investors.

• The “Bet Big or Go Home” Ethos: Both guests shared a fundamental belief that for Indian pharma to succeed globally, it couldn’t play it safe. This aggressive, forward-thinking mindset was crucial in building two of India’s most significant pharmaceutical companies.

• Navigating the Shifting Pharmaceutical Landscape: The conversation addresses the current crisis in Big Pharma, with patents expiring, pipelines thinning, and Chinese companies emerging as key players in landmark deals. It underscores the increasing importance of AI in every lab and the obsolescence of old business models.

• The Role of Luck and Strategic Bets: Guests acknowledge that while effort is paramount, luck plays a significant role. They discuss how entering less competitive therapy areas and riding the wave of growing chronic diseases in India provided a crucial advantage. Glenn Saldanha shared the arduous journey of Glenmark, including significant setbacks and the spin-off of Glenmark Innovation, emphasizing the long-term commitment to innovation.

• The Indian Pharma Opportunity and Global Dynamics: The discussion touches upon India’s potential to impact global drug-making and the evolving regulatory environment. There’s a focus on the potential for India to become a significant player in innovation, with government support, a large patient pool, and growing scientific capabilities.

• Leveraging AI and Future Growth: The conversation highlights the potential of AI to accelerate drug development, particularly in small molecule discovery. The focus is on moving up the value chain towards late-stage development and commercialization, with a significant number of innovative assets entering the market in the next 5-10 years.

💡 Key Insights & Memorable Moments

• A powerful insight into the founders’ mindsets: “If Indian pharma has to make it big, it can’t play it safe.”

• The acknowledgement of “luck” in business, but framed within strategic positioning: “We were at the right place right time.”

• The contrast between building companies through capital discipline and occupying market gaps versus betting on long-term, unfashionable innovation.

• A surprising revelation about the historical lack of R&D infrastructure in India, contrasting with the current push for innovation.

• The idea that “running a business based on what investors think you should be doing is a fool’s errand,” emphasizing the importance of a founder’s vision.

🎯 Actionable Takeaways

1. Embrace calculated risks for long-term innovation: Don’t shy away from investing in novel research, even when it’s unfashionable or perceived as risky, as this can lead to significant breakthroughs and market leadership.
2. Focus on underserved markets and unmet needs: Identify and capitalize on therapeutic areas or patient populations that are currently neglected by the broader industry, as Dilip Shanghvi did successfully.
3. Leverage technology and data analytics for acceleration: Invest in and integrate advanced technologies like AI to expedite drug discovery, clinical trial processes, and regulatory submissions.
4. Cultivate a resilient mindset through setbacks: View failures and challenges not as endpoints but as learning opportunities, as exemplified by Glenn Saldanha’s journey with Glenmark.
5. Foster an environment conducive to innovation: Work towards creating ecosystem-level support for R&D, attracting talent, and ensuring that the market and regulatory bodies value innovation.

👥 Guest Information

• Dilip Shanghvi: Executive Chairman of Sun Pharma. His expertise lies in building pharmaceutical companies through strategic capital discipline and market expansion, particularly in generic and specialty pharmaceuticals. He is credited with transforming Sun Pharma into one of the world’s largest generic drug manufacturers by acquiring and integrating other companies and identifying neglected market opportunities.
• Glenn Saldanha: Managing Director at Glenmark Pharma. His expertise is in driving innovation and R&D within the pharmaceutical sector, focusing on novel drug discovery and development. He spearheaded Glenmark’s shift towards innovation, investing heavily in research for new molecules and biologics, and is recognized for his long-term vision in the face of industry skepticism.